Skip Nav Destination
Issues
1 June 2017
-
Cover Image
Cover Image
ABOUT THE COVER
The cover illustrates the binding mode of ibrutinib with homology modeled ABCB1 predicted by XP-Glide. The docked conformation of ibrutinib as ball and stick model is shown within the large hydrophobic cavity of ABCB1. Important amino acids are depicted as sticks with the carbon atoms colored in green, hydrogen in white, nitrogen in blue, oxygen in red and sulfur in yellow, whereas ibrutinib is shown with the same color scheme as above except carbon atoms are represented in orange. Dotted black line indicates hydrogen-bonding interactions. Molecular surface of homology modeled ABCB1 was colored in yellow which indicated the hydrophobic nature of ibrutinib-binding pocket. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Small Molecule Therapeutics
Author Choice
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P.S. Perera; Eleonora Jovcheva; Laurence Mevellec; Jorge Vialard; Desiree De Lange; Tinne Verhulst; Caroline Paulussen; Kelly Van De Ven; Peter King; Eddy Freyne; David C. Rees; Matthew Squires; Gordon Saxty; Martin Page; Christopher W. Murray; Ron Gilissen; George Ward; Neil T. Thompson; David R. Newell; Na Cheng; Liang Xie; Jennifer Yang; Suso J. Platero; Jayaprakash D. Karkera; Christopher Moy; Patrick Angibaud; Sylvie Laquerre; Matthew V. Lorenzi
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Hui Zhang; Atish Patel; Yi-Jun Wang; Yun-Kai Zhang; Rishil J. Kathawala; Long-Hui Qiu; Bhargav A. Patel; Li-Hua Huang; Suneet Shukla; Dong-Hua Yang; Suresh V. Ambudkar; Li-Wu Fu; Zhe-Sheng Chen
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Nicolas Floc'h; Susan Ashton; Paula Taylor; Dawn Trueman; Emily Harris; Rajesh Odedra; Kim Maratea; Nicola Derbyshire; Jacqueline Caddy; Vivien N. Jacobs; Maureen Hattersley; Shenghua Wen; Nicola J. Curtis; James E. Pilling; Elizabeth J. Pease; Simon T. Barry
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Casey G. Langdon; James T. Platt; Robert E. Means; Pinar Iyidogan; Ramanaiah Mamillapalli; Michael Klein; Matthew A. Held; Jong Woo Lee; Ja Seok Koo; Christos Hatzis; Howard S. Hochster; David F. Stern
Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Stuart W. Ember; Que T. Lambert; Norbert Berndt; Steven Gunawan; Muhammad Ayaz; Marilena Tauro; Jin-Yi Zhu; Paula J. Cranfill; Patricia Greninger; Conor C. Lynch; Cyril H. Benes; Harshani R. Lawrence; Gary W. Reuther; Nicholas J. Lawrence; Ernst Schönbrunn
Large Molecule Therapeutics
A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio
Ming-Hsien Chien; Wei-Min Chang; Wei-Jiunn Lee; Yu-Chan Chang; Tsung-Ching Lai; Derek V. Chan; Rahul Sharma; Yuan-Feng Lin; Michael Hsiao
Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Akihisa Kato; Hiromi Kataoka; Shigenobu Yano; Kazuki Hayashi; Noriyuki Hayashi; Mamoru Tanaka; Itaru Naitoh; Tesshin Ban; Katsuyuki Miyabe; Hiromu Kondo; Michihiro Yoshida; Yasuaki Fujita; Yasuki Hori; Makoto Natsume; Takashi Murakami; Atsushi Narumi; Akihiro Nomoto; Aya Naiki-Ito; Satoru Takahashi; Takashi Joh
Cancer Biology and Signal Transduction
Focal Adhesion Kinase as a Potential Target in AML and MDS
Bing Z. Carter; Po Yee Mak; Xiangmeng Wang; Hui Yang; Guillermo Garcia-Manero; Duncan H. Mak; Hong Mu; Vivian R. Ruvolo; Yihua Qiu; Kevin Coombes; Nianxiang Zhang; Brittany Ragon; David T. Weaver; Jonathan A. Pachter; Steven Kornblau; Michael Andreeff
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma
Yoshiteru Ohata; Shu Shimada; Yoshimitsu Akiyama; Kaoru Mogushi; Keisuke Nakao; Satoshi Matsumura; Arihiro Aihara; Yusuke Mitsunori; Daisuke Ban; Takanori Ochiai; Atsushi Kudo; Shigeki Arii; Minoru Tanabe; Shinji Tanaka
Companion Diagnostics and Cancer Biomarkers
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.